Praxis Precision Medicines, Inc. PRAX Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Praxis Precision Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Praxis Precision Medicines, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Praxis Precision Medicines, Inc.'s total equity?
- Praxis Precision Medicines, Inc. (PRAX) reported total equity of $1.41B in Q1 2026.
- How has Praxis Precision Medicines, Inc.'s total equity changed year-over-year?
- Praxis Precision Medicines, Inc.'s total equity increased by 221.0% year-over-year, from $439.21M to $1.41B.
- What is the long-term trend for Praxis Precision Medicines, Inc.'s total equity?
- Over 5 years (2020 to 2025), Praxis Precision Medicines, Inc.'s total equity has grown at a 25.0% compound annual growth rate (CAGR), from $287.46M to $878.14M.
- What does total equity mean?
- The total net value of the company belonging to shareholders.
- How do you interpret total equity?
- An increasing trend suggests value creation or successful capital raises, while a decreasing trend may indicate significant cash burn.
- How does total equity compare across companies?
- A key metric for assessing the financial health and runway of clinical-stage biopharmaceutical companies.